<DOC>
	<DOCNO>NCT00668837</DOCNO>
	<brief_summary>Open-Label Extension double-blind effectiveness safety study R076477-SCH-305 evaluate long-term safety tolerability patient schizophrenia .</brief_summary>
	<brief_title>A 52 Week Open-label Extension Trial Following Double-blind Efficacy Safety Study R076477-SCH-305 .</brief_title>
	<detailed_description>The primary objective open-label extension trial long-term assessment safety tolerability flexibly-dosed ER OROS paliperidone ( 3 15 mg/day ) patient diagnosis schizophrenia . Other measure assess extension study include : change total Positive Negative Syndrome Scale ( PANSS ) score ; change PANSS subscale ( positive negative ) score ; overall functioning , measure Clinical Global Impression Scale-Severity ( CGI-S ) ; personal social functioning , measure Personal Social Performance Scale ( PSP ) ; quality life parameter , measure Schizophrenia Quality Life Scale , Revision 4 ( SQLS-R4 ) . Paliperidone ER OROSÂ® tablet formulation ( 3 15 mg/day ) take orally 52 week</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Study R076477SCH707 enrol patient meet DSMIV criterion schizophrenia least 1 year Eligible patient experience active symptom time enrollment PANSS total score 70 120 The openlabel extension study population comprise patient complete 6week doubleblind phase study discontinue due lack efficacy least 21 day treatment . Not eligible enter openlabel phase believe significant risk suicidal violent behavior openlabel extension trial Were pregnant Or receive injection depot antipsychotic since entry precede doubleblind phase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Paliperidone</keyword>
	<keyword>schizophrenia</keyword>
</DOC>